#### **Supplementary Information**

## CHARGE Syndrome Protein CHD7 Regulates Epigenomic Activation of Enhancers in Granule Cell Precursors and Gyrification of the Cerebellum

Naveen C. Reddy, Shahriyar P. Majidi, Lingchun Kong, Mati Nemera, Cole J. Ferguson, Michael Moore, Tassia M. Goncalves, Hai-Kun Liu, James A. J. Fitzpatrick, Guoyan Zhao, Tomoko Yamada, Azad Bonni, Harrison W. Gabel





С



е





f



Ataxia

Seizures

Tremors

0

10 20 30 40 50

-Log<sub>10</sub> (adj. P-Value)

Impaired coordination

Response to xenobiotic

Convulsive seizures

Channel responses

Touch/nociception

#### CHD7 negative P4/P22 active enhancers



#### CHD7 negative P4 specific active enhancers

d





#### Supplementary Fig. 1: Conditional CHD7 knockout in mouse cerebellum.

- a. P4 sagittal cerebellar sections from CHD7 ctrl (left) and cKO (right) mouse lines were subjected to immunohistochemistry by using antibodies recognizing CHD7 and DNA dye bisbenzimide (Hoechst). Experiment was repeated two times for each condition. Scalebar: 100um.
- b. P4 cerebellar sections from CHD7 ctrl (left) and cKO (right) mouse lines were subjected to immunohistochemistry by using antibodies recognizing CHD7 (left) and DNA dye bisbenzimide (Hoechst, right). EGL, external granule layer; ML, molecular layer; IGL, internal granule layer. Experiment was repeated two times for each condition. Scalebar: 25um.
- c. Immunoblotting of CHD7 (top) and GAPDH (bottom) in lysates of P4 mouse cerebellum harvested from CHD7 ctrl and cKO mice. Experiment was repeated three times for each condition.
- d. WashU Epigenome Browser view of a CHD7 bound P4-specific active enhancer (highlighted). ChIP-seq coverage for CHD7, H3K27ac, H3K4me1, as well as, ATACseq and RNA-seq is shown.
- e. GREAT analysis showing enriched mouse phenotypes associated with enhancers active at P4 and P22.
- f. GREAT analysis showing enriched mouse phenotypes associated with CHD7-negative enhancers active at P4 specifically (left), P4 and P22 (middle), and P22 specifically (right).
- g. Pie chart representing proportion of CHD7 occupied poised enhancers displaying RNApolII binding.



b

Total

-1.0

CHD7-

CHD7+ CHD7- C HD7+

All regions Active enhancers



С

cKO1

cKO2

Ctrl cKO Total TADs 2,311 2,306 2,373 13,559 602 1,771

5

Density

0

1.0

а

# Supplementary Fig 2: Conditional CHD7 knockout minimally alters genomic architecture and associated regulatory factors.

- a. Distribution of pooled Hi-C contacts in CHD7 ctrl and cKO cerebellum.
- b. Hi-C Spector analysis for reproducibility of CHD7 ctrl and cKO biological replicates.
- c. Table summarizing results of Hi-C analysis.
- d. Box-whisker plots showing the median, 1<sup>st</sup> quartile, 3<sup>rd</sup> quartile, and whiskers displaying the 5<sup>th</sup> and 95<sup>th</sup> percentiles of intradomain loops representing median and distribution of the log2 fold change of observed over expected Hi-C signal at CHD7 bound and unoccupied domains separated by decreasing (n=59, n=716) or increasing (n=14, n=192) ATAC-seq signal change in CHD7 cKO over ctrl.
- e. Density plots comparing the log2 fold change in H3K27ac-seq signal at CHD7 bound peaks in a contact domain with the log2 fold change in Hi-C contacts in compartmental domains (left) and loop domains (right).
- f. Box-whisker plots showing the median, 1<sup>st</sup> quartile, 3<sup>rd</sup> quartile, and whiskers displaying the 5<sup>th</sup> and 95<sup>th</sup> percentiles of CTCF occupied regions representing median and distribution of the log2 fold change of CTCF signal at all regions (n=13,758, n=1,088) and active enhancer (n=598, n=606).
- g. Box-whisker plots showing the median, 1<sup>st</sup> quartile, 3<sup>rd</sup> quartile, and whiskers displaying the 5<sup>th</sup> and 95<sup>th</sup> percentiles of RAD21 occupied regions representing median and distribution of the log2 fold change of RAD21 signal at all regions (n=15,188, n=8.623) and active enhancer (n=1,209, n=2,506).



System development Cell Morph. Cell deveopment Cell morph., neuron differentiation Regulation of cellular process Cell morph., differentiation Signaling Cell communication Neuron projection morph. Plasma membrane bound projection morph. Cell projection morph. Axonogenesis Cell part morph. Axon development Regulation of biological process Regulation of biological quality Repression of gene expression, epigenetic Chromatin silencing Cellular component morph. Locomotion Plasma membrane bound projection org. Cell projection org. Chromatin org., transcriptional repression



4

-Log<sub>10</sub> (adj. P-Value)

2

0

6

8

Developmental process Extracellular matrix org. Signal transduction Extracellular structure org. Anatomical structure development Multicellular organismal process Cell surface receptor signaling Cell differentiation Signaling Cellular developmental process Cell communication





Enhancer/gene change

	Up	Down
CHD7 -	348	144
CHD7 +	159	653

p = 9.68E-77







С

d

е

Supplementary Fig. 3: Conditional CHD7 knockout disrupts many biological processes by changing enhancer accessibility and corresponding gene expression.

- Panther gene ontology analysis of significantly dysregulated genes associated with CHD7
   ChIP-seq peaks (p <= 0.05). Significantly enriched biological processes are shown for</li>
   CHD7 activated (top, blue) and CHD7 repressed (bottom, red) genes.
- b. Density plots comparing the log2 fold change in enhancer ATAC-seq signal to the log2 fold change in RNA expression of correspond gene.
- c. Table displaying number of significantly changed enhancers in the CHD7 cKO for which transcript levels of the gene linked to that enhancer change in the same direction as the enhancer. Enhancers are paired to a gene within 100Kb and withing the same TAD. P-value = 9.68E-77, one-sided Chi-squared test.
- d. Box plots showing the median, 1<sup>st</sup> quartile, 3<sup>rd</sup> quartile, and whiskers displaying the 5<sup>th</sup> and 95<sup>th</sup> percentiles of E-P pairs representing median and distribution of the log2 fold change of observed over expected Hi-C signal at CHD7 bound (2,203) and unoccupied (2,972) domains separated by decreasing (n=116, n=558) or increasing (n=308, n=156) ATAC-seq signal change in CHD7 cKO over ctrl.
- Density plots comparing the log2 fold change in domain ATAC-seq signal to the log2 fold change in RNA expression of correspond genes.
- f. Box-whisker plots showing the median, 1<sup>st</sup> quartile, 3<sup>rd</sup> quartile, and whiskers displaying the 5<sup>th</sup> and 95<sup>th</sup> percentiles of CHD7 bound proximal genes within TADs representing median and distribution of the log2 fold change of RNA signal in CHD7 cKO over CHD7 control. Active enhancers were divided into three groups based on significantly increasing or decreasing changes in ATAC-seq signal. We then quantified the change in

gene expression of corresponding genes within groups defined by ATAC-seq changes. Boxplots are divided into groups of decreasing (left; n=399, n=399, n=398) and increasing (right; n=113, n=113, n=112) ATAC-seq fold change \*\*p < 0.01, unpaired two-sided t-test, Tukey's multiple comparison test.







g

h

d

С













а

Supplementary Fig. 4: Cerebellar microgyria appears at the proliferative stage of granule cell precursor development.

- Nano CT mediolateral scans of lobule IX of Ctrl (left) and cKO (right) p56 mouse cerebella. Scale bar: 2mm.
- b. Nano CT midline sagittal scans of Ctrl (left) and cKO (right) p56 mouse cerebella. Scale bar: 2mm.
- c. Bar graphs showing % change in total cerebellar (Cb) anterior-posterior (AP) and dorsoventral (DV) measurement upon CHD7 cKO in p56 mice (n=3 for each condition). Length is shown as mean □ s.e.m for each measurement. \*p<0.05, \*\*p<0.01 Paired two-sided t-test.</li>
- Immunohistochemistry analysis of Ctrl and cKO p56 mice with antibodies recognizing GFAP, a marker of glial cells, and Hoechst. Experiment was repeated two times for each condition. Scalebar: 100um.
- Bar graph showing internal granule cell layer (IGL) thickness +/- s.e.m. of lobules I, III, and V for Ctrl and cKO p56 mice (n=3 for each condition). p= 0.0382 (I), p=0.0072 (III), p=0.9556 (V) Two-way ANOVA test; ns, not significant.
- f. Nano CT scans were taken of multiple stages of granule cell development. Onset of postnatal GCP proliferation (P3: proliferative); post GCP proliferation (P14: postproliferative); adult granule cells (P60: adult). Scale bar: 500um (top), 2mm (middle and bottom).
- g. Graph displaying the time course of formation of additional gyri in CHD7 cKO mice.

h. Graphs displaying the thickness of the EGL +/- s.e.m. along the mediolateral plane of Ctrl and cKO P3 (top) and P4 (bottom) mice. Midline (M), Sulcus (S). \*p<0.05, \*\*p<0.01, \*\*\*\*p<0.0001.Two-way ANOVA.</li>







0 Forelimb Hindlimb 0 Forelimb Hindlimb Supplementary Fig. 5: Loss of CHD7 results in mediolateral differential expansion of granule cell precursors without perturbing post-proliferative granule cell development and gross motor output of mouse cerebellum.

- a. Immunohistochemistry analysis of posterior cerebellum of Ctrl and cKO mice (n=3 for each condition) with antibodies recognizing phosphorylated histone H3 (pH3), a marker of dividing cells. Dividing cells were counted in the region posterior to the secondary fissure of the cerebellum (lobules IX and X), referred to in shorthand as the posterior cerebellum. Bar graphs show mean pH3 positive cells per 100um<sup>2</sup> +/- s.e.m. ns = non-significant. Paired two-sided t-test.
- b. CHD7 Ctrl (n=3) and cKO (n=3) mice were electroporated at P6 with the pCAG-GFP vector and fixed 2 days later in order to identify migrating granule cells. Granule cells with a parallel fiber and one leading process were considered to be bipolar, while granule cells with a parallel fiber and multiple processes were considered to be multipolar.
  Percentage of bipolar and multipolar granule cells +/- s.e.m. was calculated for each mouse and analyzed for significance. One-sided Chi-square test. ns, not significant.
- c. CHD7 Ctrl (n=3) and cKO (n=3) mice were electroporated at P6 with the pCAG-GFP vector and fixed 8 days later in order to identify mature granule cells. The number of dendrites of GFP positive cells were counted in each mouse and then averaged. Bar graphs show average dendrite numbers +/- s.e.m. . Two-sided t-test. ns, not significant.
- d. Scatter plots of cross sectional P3 and P4 cerebellum area (left) and folding index (right) vs EGL length. EGL length was measured in the anterior cerebellar vermis using Nano CT sections. Area was also quantified using Nano CT sections of the anterior cerebellar vermis. Folding index is the ratio of the EGL length to the length of the anterior

cerebellar vermis. Slope of Ctrl (black line) and cKO (red line) define expansion properties of cerebellum.

e. Analysis of body size and gait dynamics by Digigait assay did not reveal deficits in sexmatched cKO mice (n=14) relative to control (n=11) littermates on stride-related variables for both the forelimbs and hindlimbs. Data are presented as mean values +/s.e.m. Two-way ANOVA with Sidak's multiple comparison test.







Supplementary Fig. 6: CHD7 expression and genomic-wide occupancy in granule cell precursors of fetal human cerebellum.

- Immunohistochemistry analysis of 22 gestational week human cerebellum with Hoechst and antibodies recognizing PAX6 (top), calbindin (middle), and S100B (bottom).
   Experiment was performed once on the individual human sample. Scale bar: 100um.
- b. Heatmap of ChIP-seq signal for human CHD7 (purple), human H3K27ac (blue), and input (black) centered on human CHD7 genomic binding sites (n=17,100).
- c. YUE lab Hi-C browser (http://3dgenome.fsm.northwestern.edu/view.php) view of the TUBB2B and MAP1B loci showing the location of conserved CHD7 bound regulatory elements found within conserved topologically associated domains surrounding the TUBB2B and MAP1B loci in mouse cerebellar and in human prefrontal cortical tissue. Mouse data is aligned to mm10 and human data is aligned to hg19. TAD domains are shown in yellow and blue. Enhancers (light blue) and gene loci (black) are shown below TAD domains. Data from Schmitt et al., 2016.

## Supplementary Table 1: Number of reads per sequencing sample.

Sample_ID	<b>Total Reads</b>
P4_ChIP_CTCF_cKO_1	30239450
P4_ChIP_CTCF_cKO_2	23882825
P4_ChIP_CTCF_cKO_3	26785055
P4_ChIP_CTCF_Ctrl_1	23887827
P4_ChIP_CTCF_Ctrl_2	22184978
P4_ChIP_CTCF_Ctrl_3	30176045
P4_ChIP_RAD21_cKO_1	25335111
P4_ChIP_RAD21_cKO_2	28519279
P4_ChIP_RAD21_cKO_3	21699710
P4_ChIP_RAD21_Ctrl_1	20240974
P4_ChIP_RAD21_Ctrl_2	22291115
P4_ChIP_RAD21_Ctrl_3	21406366
P4_ChIP_RNAP2_cKO_1	24645904
P4_ChIP_RNAP2_cKO_2	31224374
P4_ChIP_RNAP2_cKO_3	21358159
P4_ChIP_RNAP2_Ctrl_1	25754990
P4_ChIP_RNAP2_Ctrl_2	28502519
P4_ChIP_RNAP2_Ctrl_3	24704851
P4_ChIP_H3K27ac_cKO_1	29513035
P4_ChIP_H3K27ac_cKO_2	22791409
P4_ChIP_H3K27ac_cKO_3	27244501
P4_ChIP_H3K27ac_Ctrl_1	28288347
P4_ChIP_H3K27ac_Ctrl_2	24439089
P4_ChIP_H3K27ac_Ctrl_3	31269223
P4_ChIP_H3K4me1_Ctrl_1	24185291
P4_ChIP_H3K4me1_Ctrl_2	25040047
P4_ChIP_H3K4me1_Ctrl_3	24006539
P4_ChIP_H3K4me1_cKO_2	19872430
P4_ChIP_H3K4me1_cKO_3	25111457
P4_ChIP_H3K4me3_Ctrl	20774101
P4_Input_cKO	24975122
P4_Input_Ctrl	22278616
P4_ChIP_CHD7_Ctrl_1	36321205
P4_ChIP_CHD7_Ctrl_2	34366964
P4_ChIP_CHD7_cKO	60536381
P4_CHD7_Input_cKO	34726055
P4_CHD7_Input_Ctrl	36168280
P4_ATAC_Ctrl_1	124020174
P4_ATAC_Ctrl_2	120750568
P4_ATAC_Ctrl_3	245511484

P4_ATAC_cKO_1	119727870
P4_ATAC_cKO_2	97125142
P4_ATAC_cKO_3	133327052
P4_RNA_Ctrl_1	43762737
P4_RNA_Ctrl_2	44657732
P4_RNA_Ctrl_3	52311021
P4_RNA_Ctrl_4	40845072
P4_RNA_Ctrl_5	44113339
P4_RNA_cKO_1	38058427
P4_RNA_cKO_2	39757228
P4_RNA_cKO_3	41606151
P4_RNA_cKO_4	34955069
P4_RNA_cKO_5	34794895
22w_ChIP_Human_CHD7	46219752
22w_ChIP_Human_H3K27ac	20465108
22w_Human_Input	9049801
Hi-C_Ctrl_1	435398098
Hi-C_Ctrl_2	432510890
Hi-C_Ctrl_3	449314952
Hi-C_cKO_1	417558715
Hi-C_cKO_2	528193699
Hi-C_cKO_3	449493952

## Supplementary Table 2: Primers used to genotype mice.

Primer Name	Sequence (5' - 3')
CHD7 floxed allele forward (Genotyping) CHD7 floxed allele reverse (Genotyping)	TGCAGATGGGACGTTTTCAG CTGCAAGAACACAGGGGCAAG
Control (without Atoh1-Cre transgene) forward (Genotyping) Control (without Atoh1-Cre transgene) reverse (Genotyping) Atoh1-Cre transgene forward (Genotyping) Atoh1-Cre transgene reverse primer (Genotyping)	AAGGTGTGGTTCCAGAAT CTCTCCACCAGAAGGCTG GATCCGAAAAGAAAA